Integra lifesciences (NASDAQ: IART) and Bio-Rad Laboratories (NYSE:BIO) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and profitability.
Insider and Institutional Ownership
90.4% of Integra lifesciences shares are held by institutional investors. Comparatively, 64.5% of Bio-Rad Laboratories shares are held by institutional investors. 5.1% of Integra lifesciences shares are held by company insiders. Comparatively, 28.3% of Bio-Rad Laboratories shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This table compares Integra lifesciences and Bio-Rad Laboratories’ revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Integra lifesciences||$1.19 billion||3.78||$64.74 million||$1.94||29.32|
|Bio-Rad Laboratories||$2.16 billion||3.64||$114.74 million||$4.10||64.47|
Bio-Rad Laboratories has higher revenue and earnings than Integra lifesciences. Integra lifesciences is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.
This is a summary of current ratings and price targets for Integra lifesciences and Bio-Rad Laboratories, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Integra lifesciences presently has a consensus price target of $55.90, indicating a potential downside of 1.72%. Bio-Rad Laboratories has a consensus price target of $298.75, indicating a potential upside of 13.03%. Given Bio-Rad Laboratories’ stronger consensus rating and higher probable upside, analysts plainly believe Bio-Rad Laboratories is more favorable than Integra lifesciences.
This table compares Integra lifesciences and Bio-Rad Laboratories’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Risk & Volatility
Integra lifesciences has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Bio-Rad Laboratories has a beta of 0.94, indicating that its stock price is 6% less volatile than the S&P 500.
Bio-Rad Laboratories beats Integra lifesciences on 9 of the 14 factors compared between the two stocks.
About Integra lifesciences
Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies. It offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. The company also sells approximately 60,000 instrument patterns, and surgical and lighting products to hospitals and surgery centers, as well as dental, podiatry, and veterinary offices. In addition, it provides regenerative technology products for the treatment of acute and chronic wounds; and surgical tissue repair products for hernia repair, peripheral nerve repair and protection, and tendon repair. Further, the company sells hardware products, such as bone and joint fixation, and joint replacement devices; implants; and instruments, which provide for the orthopedic reconstruction of bone in the hand, wrist, elbow, and shoulder, as well as the foot, ankle, and leg below the knee in the extremity bone and joint reconstruction procedures. Integra LifeSciences Holdings Corporation offers its products directly through various sales forces and other distribution channels in the United States, Europe, and internationally. The company was founded in 1989 and is headquartered in Plainsboro, New Jersey.
About Bio-Rad Laboratories
Bio-Rad Laboratories, Inc. manufactures and supplies products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components for life science research, healthcare, analytical chemistry, and other markets. The company operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls that serve clinical laboratories in the diagnostics market. Its products include reagents, instruments, and software which address specific niches within the in vitro diagnostics (IVD) test market. This segment sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. It operates in Europe, Pacific Rim, the United States, and internationally. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Receive News & Ratings for Integra lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.